Atossa Therapeutics (NASDAQ:ATOS) Stock Rating Reaffirmed by HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 404.20% from the company’s previous close.

A number of other equities analysts also recently commented on ATOS. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the stock a “buy” rating in a research note on Thursday, June 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research note on Thursday, June 20th. Finally, StockNews.com upgraded shares of Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 14th.

Atossa Therapeutics Price Performance

Atossa Therapeutics stock opened at $1.19 on Friday. Atossa Therapeutics has a 1-year low of $0.62 and a 1-year high of $2.31. The firm has a market capitalization of $149.65 million, a P/E ratio of -4.96 and a beta of 1.19. The company’s 50-day moving average is $1.39 and its 200 day moving average is $1.23.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Research analysts anticipate that Atossa Therapeutics will post -0.23 earnings per share for the current fiscal year.

Insider Activity

In other Atossa Therapeutics news, Director Jonathan Finn acquired 25,000 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the purchase, the director now owns 25,000 shares in the company, valued at $44,250. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. PFG Investments LLC bought a new position in shares of Atossa Therapeutics during the first quarter valued at approximately $43,000. Cetera Advisors LLC acquired a new stake in Atossa Therapeutics in the first quarter valued at approximately $72,000. Virtu Financial LLC acquired a new stake in Atossa Therapeutics in the first quarter valued at approximately $151,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Atossa Therapeutics in the third quarter valued at approximately $98,000. Finally, Vanguard Group Inc. boosted its stake in Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after acquiring an additional 78,269 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.